The state-controlled Antibiotice Iasi pharmaceuticals manufacturer has won a €11 million tender in the UK for the supply of five injectable anti-infective drugs for hospitals, according to a company statement. The tender was organized by the UK Department of Health and deliveries will start in January 2022 and will last for two years. The drugs can be used including in the treatment of bacterial superinfections associated with COVID-9 virus infection, says Antibiotice director Ioan Nani.
“The recently concluded contract is worth 11 million euros, which allows us to consolidate our business in the future, as well as reconfirming our status as a drug manufacturer accepted by one of the largest regulated markets in Western Europe … It is further proof that our country can also perform well, that Romania has a future!”, said Nani.
Accessing the UK market is part of Antibiotice’s territorial expansion strategy and is part of the company’s long-term Strategic Development and Organisation Plan, company representatives added. Antibiotice has ongoing projects in countries such as Brazil, Australia and Northern European countries (Finland, Sweden, Norway, Denmark) that will allow the company to develop its presence in these markets and will result in significant sales.
In recent years, Antibiotice has won important tenders for anti-infective drugs in the United States, where it supplies a good part of the consumption of products in this market, Western Europe, South East Asia and the tender organized by the European Commission (2020) to provide member countries with the necessary stocks of beta-lactam antibiotics during pandemics.
The company is state-controlled through the Ministry of Health and is listed on the Stock Exchange.